Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase
- 27 April 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (15), 8025-8042
- https://doi.org/10.1021/acs.jmedchem.9b02035
Abstract
Inhibition of monopolar spindle 1 (MPS1) kinase represents a novel approach to cancer treatment: instead of arresting the cell cycle in tumor cells, cells are driven into mitosis irrespective of DNA damage and unattached/misattached chromosomes, resulting in aneuploidy and cell death. Starting points for our optimization efforts with the goal to identify MPS1 inhibitors were two HTS hits from the distinct chemical series “triazolopyridines” and “imidazopyrazines”. The major initial issue of the triazolopyridine series was the moderate potency of the HTS hits. The imidazopyrazine series displayed more than 10-fold higher potencies; however, in the early project phase, this series suffered from poor metabolic stability. Here, we outline the evolution of the two hit series to clinical candidates BAY 1161909 and BAY 1217389 and reveal how both clinical candidates bind to the ATP site of MPS1 kinase, while addressing different pockets utilizing different binding interactions, along with their synthesis and preclinical characterization in selected in vivo efficacy models.Keywords
This publication has 21 references indexed in Scilit:
- Leader of the SAC: molecular mechanisms of Mps1/TTK regulation in mitosisOpen Biology, 2018
- Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization ApproachJournal of Medicinal Chemistry, 2016
- Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical UtilityPLOS ONE, 2015
- Discovery of Imidazo[1,2-b]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative ActivityJournal of Medicinal Chemistry, 2015
- Characterization of novel MPS1 inhibitors with preclinical anticancer activityCell Death & Differentiation, 2013
- Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Mps1Molecular Cancer Therapeutics, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Targeting the Mitotic Checkpoint to Kill Tumor CellsHormones and Cancer, 2010
- Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 KinaseCancer Research, 2010
- Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1–C-Mad2 core complexThe Journal of cell biology, 2010